Biotechnology

The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare

Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...

2021-09-08 19:00 3106

Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver dise...

2021-09-08 08:30 1454

Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-09-08 08:00 5726

Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability

PALO ALTO, Calif., Sept. 7, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe , https://ipeace.com/), aPalo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinica...

2021-09-08 02:00 736

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...

2021-09-07 20:00 4529

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...

2021-09-07 19:00 1210

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...

2021-09-07 18:00 1174

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited announced the appointment ofGiuliano Perfetti as its Chief Executive Officer. Mr. Giuliano Perfetti joins as CEO Jubilant Bio...

2021-09-07 16:11 956

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease. -- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform ma...

2021-09-07 12:00 1837

Laureates of the 2021 Global Energy Prize Announced

MOSCOW, Sept. 6, 2021 /PRNewswire/ -- The winners of the 2021 Global Energy Prize  were announced on 6th September in Kazan. The laureates were: Russian scientists Zinfer Ismagilov and Suleyman Alak...

2021-09-06 20:00 1518

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...

2021-09-06 13:44 2885

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...

2021-09-06 09:00 708

The National Medical Products Administration (NMPA) issues product license for Abiraterone acetate 250 mg, Bioequivalance study conducted in India by Accutest Research Laboratories (I) Pvt. Ltd., one of the Top Indian CRO

BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration  (NMPA) China, announces the approval of Abiraterone acetate 250mg ofQilu Pharmaceuticals for marketing purpose. Applicable Bioequivalance ...

2021-09-06 08:00 1096

AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases

BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...

2021-09-06 08:00 490

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...

2021-09-06 08:00 1378

Avidity Science Announces Agreement to Divest Lab Products & Harford Systems

WATERFORD, Wis., Sept. 4, 2021 /PRNewswire/ -- Avidity Science, a worldwide leader in life science research tools, today announces it has sold its subsidiaries of Lab Products, LLC. and Harford Systems, LLC. to Gen Cap America, Inc. ("Gen Cap"), a private equity firm focused on lower middle marke...

2021-09-04 00:00 2901

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II c...

2021-09-03 20:00 1014

Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment

SHANGHAI, Sept. 2, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, today announced the clearance of the Investigational New Drug (IND) application for Phase III study of ARVN003 (pilocarpine microdose o...

2021-09-03 08:00 830

Clinical trial provides preliminary evidence of a cure for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and Long Covid

BURLINGAME, Calif., Sept. 3, 2021 /PRNewswire/ -- Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS.  The company intends to test CT38 in Long Covid, the post-acut...

2021-09-03 06:00 1325

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a Strain of Yeast Probiotic Effective Against Diarrhea

YICHANG, China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company inChina, announced its nutritional R&D team has developed a new strain of yeast probiotic,Saccharomyces boulardii Bld-3 (S. boulardii Bld-3) ...

2021-09-02 22:43 1928
1234567 ... 232